These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 38032104)

  • 61. Analysis of lorlatinib analogs reveals a roadmap for targeting diverse compound resistance mutations in ALK-positive lung cancer.
    Shiba-Ishii A; Johnson TW; Dagogo-Jack I; Mino-Kenudson M; Johnson TR; Wei P; Weinrich SL; McTigue MA; Walcott MA; Nguyen-Phuong L; Dionne K; Acker A; Kiedrowski LA; Do A; Peterson JL; Barth JL; Yeap BY; Gainor JF; Lin JJ; Yoda S; Hata AN
    Nat Cancer; 2022 Jun; 3(6):710-722. PubMed ID: 35726063
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Integrated proximal proteomics reveals IRS2 as a determinant of cell survival in ALK-driven neuroblastoma.
    Emdal KB; Pedersen AK; Bekker-Jensen DB; Lundby A; Claeys S; De Preter K; Speleman F; Francavilla C; Olsen JV
    Sci Signal; 2018 Nov; 11(557):. PubMed ID: 30459283
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Lorlatinib for the treatment of patients with non-small cell lung cancer.
    Akamine T; Toyokawa G; Tagawa T; Yamazaki K; Seto T; Takeo S; Mori M
    Drugs Today (Barc); 2019 Feb; 55(2):107-116. PubMed ID: 30816885
    [TBL] [Abstract][Full Text] [Related]  

  • 64. The Potent ALK Inhibitor Brigatinib (AP26113) Overcomes Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in Preclinical Models.
    Zhang S; Anjum R; Squillace R; Nadworny S; Zhou T; Keats J; Ning Y; Wardwell SD; Miller D; Song Y; Eichinger L; Moran L; Huang WS; Liu S; Zou D; Wang Y; Mohemmad Q; Jang HG; Ye E; Narasimhan N; Wang F; Miret J; Zhu X; Clackson T; Dalgarno D; Shakespeare WC; Rivera VM
    Clin Cancer Res; 2016 Nov; 22(22):5527-5538. PubMed ID: 27780853
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Targeting anaplastic lymphoma kinase in neuroblastoma.
    Umapathy G; Mendoza-Garcia P; Hallberg B; Palmer RH
    APMIS; 2019 May; 127(5):288-302. PubMed ID: 30803032
    [TBL] [Abstract][Full Text] [Related]  

  • 66. The accelerated path of ceritinib: Translating pre-clinical development into clinical efficacy.
    Mok TSK; Crino L; Felip E; Salgia R; De Pas T; Tan DSW; Chow LQM
    Cancer Treat Rev; 2017 Apr; 55():181-189. PubMed ID: 28427013
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Efficacy of Lorlatinib in Treatment-Naive Patients With ALK-Positive Advanced NSCLC in Relation to EML4::ALK Variant Type and ALK With or Without TP53 Mutations.
    Bearz A; Martini JF; Jassem J; Kim SW; Chang GC; Shaw AT; Shepard DA; Dall'O' E; Polli A; Thurm H; Zalcman G; Garcia Campelo MR; Penkov K; Hayashi H; Solomon BJ
    J Thorac Oncol; 2023 Nov; 18(11):1581-1593. PubMed ID: 37541389
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Phase II Study of Lorlatinib in Patients With Anaplastic Lymphoma Kinase-Positive Lung Cancer and CNS-Specific Relapse.
    Dagogo-Jack I; Oxnard GR; Evangelist M; Digumarthy SR; Lin JJ; Gainor JF; Murphy JF; Rabin MS; Heist RS; Muzikansky A; Shaw AT
    JCO Precis Oncol; 2022 May; 6():e2100522. PubMed ID: 35584349
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Dissecting the role of ALK double mutations in drug resistance to lorlatinib with in-depth theoretical modeling and analysis.
    Zhang X; Tong J; Wang T; Wang T; Xu L; Wang Z; Hou T; Pan P
    Comput Biol Med; 2024 Feb; 169():107815. PubMed ID: 38128254
    [TBL] [Abstract][Full Text] [Related]  

  • 70. TKI sensitivity patterns of novel kinase-domain mutations suggest therapeutic opportunities for patients with resistant ALK+ tumors.
    Amin AD; Li L; Rajan SS; Gokhale V; Groysman MJ; Pongtornpipat P; Tapia EO; Wang M; Schatz JH
    Oncotarget; 2016 Apr; 7(17):23715-29. PubMed ID: 27009859
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Rapid and durable response to fifth-line lorlatinib plus olaparib in an ALK -rearranged, BRCA2-mutated metastatic lung adenocarcinoma patient with critical tracheal stenosis: a case report.
    Jin C; He Z; Guo M; Liu S; Wang Y; Qiu J; Li C; Wu D
    Anticancer Drugs; 2022 Aug; 33(7):696-700. PubMed ID: 35324529
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Activation of IGF-1R pathway and NPM-ALK G1269A mutation confer resistance to crizotinib treatment in NPM-ALK positive lymphoma.
    Li Y; Wang K; Song N; Hou K; Che X; Zhou Y; Liu Y; Zhang J
    Invest New Drugs; 2020 Jun; 38(3):599-609. PubMed ID: 31177400
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Concomitant resistance mechanisms to multiple tyrosine kinase inhibitors in ALK-positive non-small cell lung cancer.
    Yu Y; Ou Q; Wu X; Bao H; Ding Y; Shao YW; Lu S
    Lung Cancer; 2019 Jan; 127():19-24. PubMed ID: 30642546
    [TBL] [Abstract][Full Text] [Related]  

  • 74. From preclinical efficacy to 2022 (36.7 months median follow -up) updated CROWN trial, lorlatinib is the preferred 1st-line treatment of advanced ALK+ NSCLC.
    Ou SI; Lee ATM; Nagasaka M
    Crit Rev Oncol Hematol; 2023 Jul; 187():104019. PubMed ID: 37187318
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Comparative safety of anaplastic lymphoma kinase tyrosine kinase inhibitors in advanced anaplastic lymphoma kinase-mutated non-small cell lung cancer: Systematic review and network meta-analysis.
    Luo Y; Zhang Z; Guo X; Tang X; Li S; Gong G; Gao S; Zhang Y; Lin S
    Lung Cancer; 2023 Oct; 184():107319. PubMed ID: 37597303
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Antibody targeting of anaplastic lymphoma kinase induces cytotoxicity of human neuroblastoma.
    Carpenter EL; Haglund EA; Mace EM; Deng D; Martinez D; Wood AC; Chow AK; Weiser DA; Belcastro LT; Winter C; Bresler SC; Vigny M; Mazot P; Asgharzadeh S; Seeger RC; Zhao H; Guo R; Christensen JG; Orange JS; Pawel BR; Lemmon MA; Mossé YP
    Oncogene; 2012 Nov; 31(46):4859-67. PubMed ID: 22266870
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Overcoming EGFR Bypass Signal-Induced Acquired Resistance to ALK Tyrosine Kinase Inhibitors in ALK-Translocated Lung Cancer.
    Miyawaki M; Yasuda H; Tani T; Hamamoto J; Arai D; Ishioka K; Ohgino K; Nukaga S; Hirano T; Kawada I; Naoki K; Hayashi Y; Betsuyaku T; Soejima K
    Mol Cancer Res; 2017 Jan; 15(1):106-114. PubMed ID: 27707887
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Fibroblast growth factor receptor 3 overexpression mediates ALK inhibitor resistance in ALK-rearranged non-small cell lung cancer.
    Sakashita T; Yanagitani N; Koike S; Low SK; Takagi S; Baba S; Takeuchi K; Nishio M; Fujita N; Katayama R
    Cancer Sci; 2022 Nov; 113(11):3888-3900. PubMed ID: 35950895
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Upregulation of MAPK Negative Feedback Regulators and RET in Mutant ALK Neuroblastoma: Implications for Targeted Treatment.
    Lambertz I; Kumps C; Claeys S; Lindner S; Beckers A; Janssens E; Carter DR; Cazes A; Cheung BB; De Mariano M; De Bondt A; De Brouwer S; Delattre O; Gibbons J; Janoueix-Lerosey I; Laureys G; Liang C; Marchall GM; Porcu M; Takita J; Trujillo DC; Van Den Wyngaert I; Van Roy N; Van Goethem A; Van Maerken T; Zabrocki P; Cools J; Schulte JH; Vialard J; Speleman F; De Preter K
    Clin Cancer Res; 2015 Jul; 21(14):3327-39. PubMed ID: 25805801
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Efficacy and safety of first-line treatments for patients with advanced anaplastic lymphoma kinase mutated, non-small cell cancer: A systematic review and network meta-analysis.
    Peng Y; Zhao Q; Liao Z; Ma Y; Ma D
    Cancer; 2023 Apr; 129(8):1261-1275. PubMed ID: 36748799
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.